Curran Simpson Sells 7,624 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) CEO Curran Simpson sold 7,624 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $10.03, for a total transaction of $76,468.72. Following the transaction, the chief executive officer owned 236,973 shares of the company’s stock, valued at approximately $2,376,839.19. This represents a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Curran Simpson also recently made the following trade(s):

• On Wednesday, September 10th, Curran Simpson sold 7,734 shares of REGENXBIO stock. The stock was sold at an average price of $10.02, for a total transaction of $77,494.68.

REGENXBIO Price Performance

RGNX stock opened at $10.58 on Friday. The company has a 50 day simple moving average of $8.96 and a 200 day simple moving average of $8.55. The stock has a market cap of $534.40 million, a price-to-earnings ratio of -3.08 and a beta of 1.17. REGENXBIO Inc. has a 1 year low of $5.03 and a 1 year high of $12.22.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). The company had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new stake in shares of REGENXBIO during the first quarter worth $35,000. Brooklyn Investment Group increased its position in shares of REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after buying an additional 3,466 shares during the period. Steward Partners Investment Advisory LLC increased its position in shares of REGENXBIO by 754.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after buying an additional 5,000 shares during the period. Captrust Financial Advisors acquired a new stake in shares of REGENXBIO during the second quarter worth $85,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of REGENXBIO during the first quarter worth $74,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Barclays decreased their price target on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Royal Bank Of Canada decreased their price target on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Finally, Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.